TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
IBIO

iBio, Inc.

Healthcare · Biotechnology

1.10$ +1.4% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Cash Flow

All figures per share in USD.

Tick rows to compare them in a chart (up to 4)

Cash Flow IBIO
Line item 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
-4.53 -6.13 -499.58 -430.08 -861.97 -760.62 -490.99 -326.85 -330.44 -498.46 -738.58 -633.99 -369.20 -106.26 -76.84 -2,167.30 -49.71 -4.84 -1.46 -0.22
1.72 1.31 70.06 61.73 60.84 41.73 34.22 28.67 25.39 58.05 94.04 80.38 46.21 17.84 6.17 217.35 2.25 0.33 0.03 0.00
– – 3.22 26.34 451.10 339.59 127.89 85.36 63.92 76.88 56.67 36.21 6.37 3.09 4.05 250.95 7.17 0.53 0.15 0.01
– – – – – -122.65 75.54 89.89 67.28 23.77 56.67 39.08 11.10 3.09 4.81 325.77 44.71 – – –
2.44 0.88 -102.28 312.94 -85.56 17.06 26.83 -6.35 40.21 22.66 16.27 4.14 38.39 3.74 -28.51 185.93 9.59 -0.83 0.05 0.02
4.31 1.53 397.92 105.67 15.19 31.02 19.74 20.57 15.04 4.20 89.38 50.75 26.15 9.19 13.19 420.25 9.37 0.05 0.00 0.01
-5.67 -1.53 -399.05 -105.67 -15.19 -31.02 -19.74 -20.57 -15.04 -4.20 -89.38 -50.75 -26.15 -9.19 -67.68 -293.95 11.45 0.24 0.07 -0.31
– – – – – – 0.00 0.00 0.00 0.00 0.00 0.00 – 171.67 – – 0.82 – – –
– – – – – 1,143.63 388.21 281.98 759.98 446.40 0.00 -5.88 -4.20 -324.89 – 0.00 -0.06 0.00 0.00 –
– – – – – – – -44.87 -39.51 -34.89 -9.54 -8.61 -5.20 -11.63 -0.85 -334.25 -14.90 -0.30 -0.07 0.14
10.27 7.66 1,150.35 512.07 1,189.35 1,143.63 388.21 281.98 759.98 1,337.78 -9.54 1,053.80 91.22 519.09 201.50 -332.70 3.76 6.39 0.85 0.99
0.08 0.00 251.72 -23.68 312.19 351.99 -122.52 -65.43 412.90 834.88 -837.50 369.02 -304.16 403.62 56.98 -3,137.71 -34.45 1.79 -0.54 0.46
-8.84 -7.66 -897.50 -535.75 -877.16 -791.64 -510.73 -347.42 -345.48 -502.66 -827.97 -684.74 -395.36 -115.45 -90.04 -2,587.55 -59.08 -4.90 -1.46 -0.23

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?